Applied DNA Sciences Files S-1/A Amendment

TL;DR

APDN filed an S-1/A on Jan 10, 2025. SEC stuff.

AI Summary

Applied DNA Sciences, Inc. filed an amendment (S-1/A) on January 10, 2025, to its registration statement. The company, formerly known as ProHealth Medical Technologies Inc., is incorporated in Delaware and headquartered in Stony Brook, NY. This filing relates to the Securities Act of 1933.

Why It Matters

This S-1/A filing indicates that Applied DNA Sciences is actively engaging with the SEC regarding its securities, which could signal upcoming corporate actions or financial reporting updates.

Risk Assessment

Risk Level: low — This filing is a routine amendment to a registration statement and does not inherently present new risks.

Key Numbers

• 333-283315 — SEC File Number (Identifies the specific registration statement being amended.)
• 0930 — Fiscal Year End (Indicates the end of the company's fiscal year.)

Key Players & Entities

• APPLIED DNA SCIENCES INC (company) — Registrant
• 0001104659-25-002521 (filing_id) — Accession Number
• 20250110 (date) — Filing Date
• 333-283315 (registration_number) — SEC File Number
• PROHEALTH MEDICAL TECHNOLOGIES INC (company) — Former Company Name
• James A. Hayward, Ph.D., Sc.D. (person) — Chairman and Chief Executive Officer

FAQ

Key Financial Figures

• $0.001 — 0,625 shares of common stock, par value $0.001 per share (the “Common Stock&rdqu
• $0.32 — ries C Warrant has an exercise price of $0.32 per share of Common Stock, will become
• $0 — Agent warrant has an exercise price of $0.32, will become exercisable upon the St
• $0.20 — rted sale price of our Common Stock was $0.20 per share. We are a “smaller re

Filing Documents

• tm2428625d2_s1a.htm (S-1/A) — 463KB
• tm2428625d2_ex23-1.htm (EX-23.1) — 3KB
• tm2428625d2_s1-img01.jpg (GRAPHIC) — 3KB
• 0001104659-25-002521.txt ( ) — 472KB

From the Filing

As filed with the Securities and Exchange Commission on January 10, 2025. Registration StatementNo. 333-283315 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 7380 59-2262718 (State or other jurisdiction of incorporation or organization) (Primary (I.R.S. Employer Identification Number) 50 Health Sciences Drive Stony Brook, New York 11790 631-240-8800 (Address, including James A. Hayward, Ph.D., Sc.D. Chairman and Chief Executive Officer Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 631-240-8801 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Merrill M. Kraines Todd Kornfeld McDermott Will & Emery LLP One Vanderbilt Avenue New York, New York 10017-3852 (212) 547-5616 Approximate date of commencement of proposed sale to the public: From time to time after this Registration If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨ If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨ If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer Smaller reporting company Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨ The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. The information contained in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where such offer or sale is not permitted. PRELIMINARY PROSPECTUS DATED JANUARY 10, 2025 Up to 20,312,500 shares of Common Stock underlying the Series C Warrants Up to 20,312,500 shares of Common Stock underlying the Series D Warrants Up to 1,015,625 shares of Common Stock underlying the Placement Agent Warrants Applied DNA Sciences, Inc. This prospectus relates to the resale from time to time, by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the caption “Selling Stockholders,” of up to an aggregate of 41,640,625 shares of common stock, par value $0.001 per share (the “Common Stock”), which the selling stockholders (the “Selling Stockholders”) may acquire upon the exercise of outstanding warrants, consisting of (i) 20,312,500 Series C Warrants (the “Series C Warrants”), (ii) 20,312,500 Series D Warrants (“Series D Warrants”, and, together with the Series C Warrants, the “Series Warrants”) and (iii) 1,015,625 Placement Agent Warrants (“Placement Agent Warrants&rdquo

View Full Filing

View this S-1/A filing on SEC EDGAR